We report the results of an in vitro screening assay targeting the intraerythrocytic form of the malaria parasite Plasmodium falciparum using a library of 560 prenyl-synthase inhibitors. Based on "growth-rescue" and enzyme-inhibition experiments, geranylgeranyl diphosphate synthase (GGPPS) is shown to be a major target for the most potent leads, BPH-703 and BPH-811, lipophilic analogs of the bone-resorption drugs zoledronate and risedronate. We determined the crystal structures of these inhibitors bound to a Plasmodium GGPPS finding that their head groups bind to the ½Mg 2þ 3 cluster in the active site in a similar manner to that found with their more hydrophilic parents, whereas their hydrophobic tails occupy a long-hydrophobic tunnel spanning both molecules in the dimer. The results of isothermal-titration-calorimetric experiments show that both lipophilic bisphosphonates bind to GGPPS with, on average, a ΔG of −9 kcal mol −1 , only 0.5 kcal mol −1 worse than the parent bisphosphonates, consistent with the observation that conversion to the lipophilic species has only a minor effect on enzyme activity. However, only the lipophilic species are active in cells. We also tested both compounds in mice, finding major decreases in parasitemia and 100% survival. These results are of broad general interest because they indicate that it may be possible to overcome barriers to cell penetration of existing bisphosphonate drugs in this and other systems by simple covalent modification to form lipophilic analogs that retain their enzyme-inhibition activity and are also effective in vitro and in vivo. M alaria, caused by Plasmodium spp., causes approximately 1 million deaths each year (1), and there are ever-present problems due to drug resistance (2). There is, therefore, a need for new drugs and drug leads. In earlier work, we and others found that the bisphosphonate class of drugs (3) used to treat bonerelated diseases-osteoporosis, Paget disease, and hypercalcemia due to malignancy-also inhibited the growth of a range of parasitic protozoa, including Trypanosoma cruzi (4, 5), Trypanosoma brucei (4, 6), Leishmania spp. (4, 7, 8) , Toxoplasma gondii (4, 9), Cryptosporidium parvum (10, 11), Entamoeba histolytica (4, 12, 13), and Plasmodium spp. (4, 13-15). In the case of Plasmodium spp., the most potent inhibitors were not, however, the nitrogencontaining bisphosphonates such as zoledronate or risedronate (Scheme 1) used to treat bone diseases, but more lipophilic n-alkyl bisphosphonates (13). Their target in Plasmodium falciparum was not determined. However, more recently, a Plasmodium vivax geranylgeranyl diphosphate synthase (PvGGPPS) has been cloned, expressed, purified, and crystallized, and its three-dimensional structure determined (16). The enzyme is inhibited by bisphosphonates (16), so it seemed possible that it might be a target for the inhibitors discovered earlier. To investigate this possibility, we recently determined the IC 50 values for 25 bisphosphonates against PvGGPPS and compared the results for enzyme inhibition with P. falciparum growth-inhibition pIC 50 ð¼ − log 10 IC 50 Þ values (17). The correlation was very poor: R 2 ¼ 0.06. For example, zoledronate had an IC 50 of approximately 790 nM in the enzyme assay but an IC 50 ¼ 120 μM in cells, and similar results were found with several other systems with the average R 2 value being 0.30 (17) for 10 diverse assays. This observation strongly suggested that zoledronate had poor permeability in the P. falciparum/red-cell assay due to its highly polar nature (log P ¼ −2.9). However, when incorporating mathematical descriptors (such as logP) to begin to account for permeability, we found that good (R 2 ¼ 0.7) correlations between cell and enzyme activity could be obtained (17). These results indicated, at least for these types of compounds, that simply screening for good enzyme inhibitors might not be particularly informative because many such inhibitors would be unable to get into cells, and that cell assays would be much more desirable. A second set of problems with the bisphosphonate class of molecules is that they bind very tightly to bone mineral (18, 19) , resulting in their rapid removal from the bloodstream. This is, of course, a desirable feature of a bone drug but not of an antiinfective-drug lead; and in recent work, we have been developing a class of compounds called "lipophilic bisphosphonates" (20, 21) in which the 1-OH group on the bisphosphonate backbone, part of the tridentate "bone-hook," is removed and in which a variety of hydrophobic side chains are attached to the molecules to increase logP values, typically from approximately −2 or −3 to approximately 2 or 3. These lipophilic bisphosphonates have far more potent activity both in vitro and in vivo than do conventional bisphosphonates in tumor cell-growth inhibition and γδ T-cell-activation assays (20, 21) as well as against malaria parasites (14) . In this work, we elected to screen our in-house library of 560 prenyl-synthase inhibitors, developed over the past decade as anticancer drug leads and as antibacterials (20) (21) (22) (23) (24) , for their activity in P. falciparum growth inhibition inside red cells. We discovered two potent leads, BPH-703 and BPH-811 (Scheme 1), lipophilic analogs of the commercial drugs zoledronate and risedronate, and determined their crystal structures bound to P. vivax
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Results and Discussion
High-Throughput Screening (HTS). In Plasmodium spp., the initial steps in isoprenoid biosynthesis are carried out by the so-called methylerythritol phosphate (MEP) pathway, which produces isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) from pyruvate and glyceraldehyde-3-phosphate (25) (Fig. 1) . DMAPP then condenses sequentially with three molecules of IPP to form geranyl diphosphate (GPP), farnesyl diphosphate (FPP), and geranylgeranyl diphosphate (GGPP), which is then used to prenylate proteins (26) . In addition, in P. falciparum, GGPP is converted via prephytoene diphosphate to phytoene and then to carotenoids (27) ; plus, the longer-chain diphosphates are converted to quinones such as Men-4 (28) as well as dolichols (29) . In Plasmodium spp., GGPPS appears to be bifunctional, making both FPP as well as GGPP; but based on its sequence and X-ray crystallographic structure with bound inhibitors (16), the enzyme is clearly more similar to other farnesyl diphosphate synthase (FPPS) than GGPPS enzymes-as evidenced, for example, by the presence of a third Asp in the second conserved DDXXD-domain (16) , inhibition by zoledronate and risedronate (unlike human and Saccharomyces cerevisae GGPPS), and the presence of the 3Mg 2þ seen in these structures, compared to the 2Mg 2þ typically found in S. cerevisae GGPPS (30) . However, the enzyme is a more effective producer of GGPP than of FPP (16) .
The screening library consisted primarily of bisphosphonates that might inhibit Plasmodium GGPPS. In addition, we included phosphonosulfonates and related systems known to inhibit head-to-head prenyl synthases (22) (23) (24) such as dehydrosqualene synthase and squalene synthase (31) , which could also inhibit Plasmodium phytoene synthase, and cationic species (such as Ro 48-8071 and quinuclidines), some of which are known to inhibit Plasmodium cell growth (28, 32) . The structures of all 560 compounds are shown in Fig. S1 .
We first screened all compounds at 10 μM to find possible hits, using artemisinin (IC 50 ¼ 20 nM) as a positive control. There were 78 hits (defined as giving ≥70% inhibition at 10 μM) as shown in Fig. 2A , and the Z 0 factor for the control wells was 0.72 as shown in Fig. 2B . The Z 0 factor is defined (33) as
where σ c þ ∕σ c − are the standard deviations of the positive (artemisinin)/negative (phosphate-buffered saline) controls and μ c þ ∕ μ c − are the corresponding mean values (33), with Z 0 ¼ 0.72 indicating an excellent assay. Full-assay details are given in SI Methods. We then performed dose-response assays for these hits (structures shown in Fig. S2 ) to determine their IC 50 values; doseresponse curves are shown in Fig. S3 . To determine which of these compounds might be worth further investigation, we next determined their IC 50 values for inhibiting the growth of three human cell lines, to assess toxicity. Typical dose-response curves are shown in Fig. S4 . We then used a therapeutic-index plot, Fig. 2C , in which we plotted the therapeutic index (T.I.), defined as T:I: ¼ IC 50 ðhuman cell assayÞ∕IC 50 ðP: f alciparum assayÞ versus the P. falciparum pIC 50 values to find those compounds among the 78 hits with the best activity versus P. falciparum that also had the lowest toxicity to human cells. Most compounds were toxic but two: BPH-703 and BPH-811 had relatively low toxicity in these assays (IC 50 values of 133 and 28 μM, respectively) and good activity in the P. falciparum growth-inhibition assay (IC 50 ¼ 690 nM and 1 μM for BPH-703 and BPH-811, respectively). Both compounds also have favorable logP values (logP approximately 2; Table S1 ) in addition to good cell activity, as illustrated in Fig. 2D . Remarkably, of the 560 compounds Fig. 1 . Isoprenoid biosynthesis and potential targets. Bisphosphonates inhibit FPPS/GGPPS as well as the long-chain prenyl synthases involved in quinone biosynthesis, protein prenylation, and dolichol formation; phosphonosulfonates and related species inhibit head-to-tail prenyl transferases such as squalene and dehydrosqualene synthase and may target phytoene synthase in Plasmodium spp.; cationic nitrogen-containing species such as Ro48-8071 inhibit diverse prenyl transferases. DXR, deoxyxylulose-5-phosphate reductoisomerase; FTI, farnesyl transferase inhibitor; PSY, phytoene synthase; CtrM, dehydrosqualene synthase; OPPS, octaprenyl diphosphate synthase; MEP, methylerythritol phosphate; and FTase, protein farnesyl transferase. assayed, the two most promising leads were both found to be simple derivatives of the commercial drugs risedronate and zoledronate in which the 1-OH group is replaced by an H, and the aryl group contains a C 10 or C 12 , hydrophobic substituent that improves logP and is expected to reduce bone binding, as shown previously with BPH-715 (Scheme 1) (19).
Target Identification. The results presented above are of considerable interest because it can be seen that the most potent Plasmodium growth inhibitors with low toxicity to human cells are "lipophilic" analogs of the well-known bisphosphonate drugs zoledronate (Zometa®/Reclast®) and risedronate (Actonel®/ Atelvia®), both of which target FPPS (3). This discovery strongly suggested the possibility that both of these lipophilic bisphosphonates target one or more prenyl synthases. In the case of BPH-703, as illustrated in Fig. S5A , it can be seen that this molecule can be thought of as being derived from a "fusion" of the key structural features found in zoledronate (the bisphosphonate and imidazole group) with the hydrophilic diphosphate and lipophilic features found in FPP or GGPP. In previous work, we found that the lipophilic pyridinium bisphosphonate BPH-715 (Scheme 1) was a potent inhibitor of both liver-stage as well as blood-stage malaria parasites (14) , but BPH-703 is far less active than is BPH-715 against three human cell lines (approximately 133 μM vs. approximately 168 nM for BPH-715; Table S1 ). In the case of BPH-811, it can again be seen (Fig. S5A ) that this compound is simply a more lipophilic analog of risedronate in which there is a decyloxy side chain addition, and the 1-OH is replaced by H. The logP values for risedronate and zoledronate are −2.9 and −3.5, whereas those for the lipophilic bisphosphonates are much more positive (Table S1) : BPH-703 ¼ 2.5; BPH-811 ¼ 1.5, which can be expected to result in enhanced cell activity (17) .
To determine whether Plasmodium GGPPS is, in fact, a major target for the lipophilic bisphosphonates, we expressed P. vivax GGPPS (whose X-ray structure is known and which has 73% identity and 89% similarity to the P. falciparum protein) and determined dose-response curves for both inhibitors from which we find IC 50 values of 1.2 μM (BPH-703) and 2.5 μM (BPH-811), corresponding to K i values of 270 and 570 nM, consistent with a GGPPS target in P. falciparum. To further test this idea, we carried out cell-growth inhibition "rescue" experiments, as reported previously for T. brucei (34) and human tumor cell lines (20) , (Fig. S5B) clearly indicated that only GGOH (at 20 μM) fully rescued cell-growth inhibition caused by BPH-703, supporting a GGPPS target. There was only a partial rescue with FOH, and no effect with solanesol (Fig. S5C) ; similar results were seen with BPH-811 (Fig. S5 D and E) . These results are of interest because the extremely potent Plasmodium GGPPS inhibitors risedronate and zoledronate (16) have little activity in P. falciparum growth assays (4) and were not found to be hits in our initial screen, even though they have GGPPS IC 50 values of approximately 500 nM (Table S1 , 16) due, we believe, to their poor cell permeability. We next sought to determine how BPH-703 and BPH-811 bound to Plasmodium vivax GGPPS.
Crystallographic Structures of PvGGPPS-Inhibitor Complexes. As we and others reported previously (30, 35, 36) , there are four main ligand (substrate or inhibitor) binding sites in human and S. cerevisae GGPPS, illustrated in (Fig. 3A) . We next obtained the crystal structures of BPH-703 and BPH-811 bound to PvGGPPS, using cocrystallization. Full crystallographic and structure refinement details are given in Table S2 , crystallization details were as described previously (16), and electron-density results are in Fig. S6 A and B.
With PvGGPPS (Protein Data Bank ID code 3LDW), zoledronate (shown in yellow in Fig. 3B ) binds to the FPP diphosphate site and, unlike the situation found with human and S. cerevisae GGPPS, is a potent inhibitor (IC 50 510 nM, versus approximately 100 μM) of Plasmodium GGPPS (Table S1 ) due to the fact that the zoledronate bisphosphonate group binds to 3 Mg 2þ in the PvGGPPS protein, just as in human FPPS (37, 38) . With the zoledronate analog BPH-703 (cyan in Fig. 3B ), it can be seen that the bisphosphonate head group also binds to 3 Mg 2þ in the active site, just as the parent molecule zoledronate does. In addition, the imidazole group is situated in essentially the same position as found with zoledronate bound to PvGGPPS: a 0.79 Å rmsd based on a protein-structure alignment; 0.37 Å for the imidazole, Mg 2þ and bisphosphonate P, O atoms, based on a ligand∕Mg 2þ alignment. The polar head group in this lipophilic bisphosphonate thus binds in a very similar manner as does its zoledronate parent. However, the alkyl chain present in the lipophilic species BPH-703 occupies the FPP substrate-hydrophobic site (b) rather than the GGPP product (or inhibitor) site (d) seen in other GGPPS structures (30, 35, 36) .
There are several reasons for this. First, the GGPP product site found in the yeast and human enzymes is blocked by R50 (Fig. S6C) . Second, the site that houses the "tail" of the FPPanalog inhibitor, S-thiolo-FPP, is blocked by F88 (Fig. S6C) . As a result, the BPH-703 side chain can now be seen to occupy a long hydrophobic pocket that spans both molecules in the dimer (Fig. 3  B and C) . In order to accommodate the extended C 10 side chain in BPH-703, both Leu-157 in the dimer are located below the chain termini of the inhibitors, as can be seen in Fig. 3C . In the PvGGPPS GGPP structure (Fig. 3D) , the GGPP chain extends from site C (the PPi-binding site) to site b, but in this case the tunnel connecting the two molecules in the dimer is closed by Leu-157 (orange), the bent ligand chain perhaps being a consequence of the presence of the double bond in the side chain. Finally, in the zoledronate structure, there is no tunnel because there is no extended side chain (Fig. 3E ).
In the case of the lipophilic-risedronate analog, BPH-811, we again find that the bisphosphonate head group binds to a ½Mg 2þ 3 cluster, and the local structure is very similar to that seen with risedronate bound to T. cruzi FPPS (a 0.82 Å rmsd, protein alignment; 0.50 Å rmsd, ligand∕Mg 2þ local alignment, as described above), as shown in Fig. 4A . Moreover, the BPH-811 structure is very similar to that seen with BPH-703, as shown in Fig. 4B . This very similar chain length and organization results in similar tunnel formation with BPH-811 as found with BPH-703, as shown in Fig. 4C . Overall then, both PvGGPPS structures containing lipophilic bisphosphonates are characterized by binding to a ½Mg 2þ 3 cluster; close register of the risedronate and zoledronate rings in the lipophilic bisphosphonates with their more hydrophilic parent compounds (in GGPPS and/or FPPS); close register between the hydrophobic side chains in both PvGGPPS inhibitors (a 1.19 Å rmsd for 10 carbons); and formation of a continuous hydrophobic tunnel between the two molecules in the dimer into which the inhibitors bind. This tunnel formation is likely an important contributor to efficacy (in vitro and in vivo) because it may permit relatively large structural changes to the inhibitor, facilitating cell penetration, without abolishing enzyme-inhibition activity.
Isothermal Titration Calorimetry. Next, we investigated the thermodynamics of binding of BPH-703, BPH-811, as well as zoledronate and risedronate, to PvGGPPS by using isothermal titration calorimetry (ITC). The head groups in the lipophilic bisphosphonates bind to PvGGPPS in a similar manner to that seen with risedronate and zoledronate, but how does alkyl substitution affect the thermodynamics of binding?
In earlier work, we investigated the thermodynamics of binding of six bisphosphonates to FPPS from T. brucei (39) , and related results have been reported for bisphosphonates binding to human FPPS (37, 38) . With bisphosphonates having cationic side chains, binding was overwhelmingly entropy driven (39) , due to the hydrophobic effect. However, with neutral side chain containing species, binding was enthalpy driven. With PvGGPPS, binding is neither overwhelmingly entropy nor enthalpy driven. For BPH-703, the zoledronate analog, we find (Table S1 ) ΔG ¼ −8.7 kcal mol −1 with ΔH ¼ −5 kcal mol −1 and ΔS ¼ 12 cal deg −1 mol −1 (Fig. 5A) , to be compared with ΔG ¼ −9.5 kcal mol −1 , ΔH ¼ −4.8 kcal mol −1 , and ΔS ¼ 16 cal deg −1 mol −1 for zoledronate (Fig. 5B) . So alkyl substitution (and loss of the 1-OH group) results in only a small overall change in ΔG of approximately 0.8 kcal mol −1 . This result is encouraging because it indicates that making a major structural change in the inhibitor-adding a C 12 side chain-has only a relatively minor effect on GGPPS binding, consistent with the enzyme-inhibition results (Table S1 , where of course Mg 2þ and IPP-binding are also involved). This observation is in sharp contrast to the finding that BPH-703 is a potent inhibitor of P. falciparum growth in vitro, whereas the zoledronate parent has only very low activity (an IC 50 ¼ 167 μM; ref. 13): Both species inhibit the GGPPS target, but only the lipophilic species have cell activity. The same trend is seen with BPH-811 and its parent, risedronate (Fig. S7 A and B) . With BPH-811, ΔG ¼ −9.3 kcal mol −1 , ΔH ¼ −2.9 kcal mol −1 , and ΔS ¼ 21 cal deg −1 mol −1 (Table S1 ) whereas for the risedronate parent, ΔG ¼ −9.3 kcal mol −1 , ΔH ¼ −2.5 kcal mol −1 and ΔS ¼ 25 cal deg −1 mol −1 . So, in both cases, conversion of the parent bisphosphonates to the more lipophilic analogs, expected to have enhanced cell/tissue permeability (17) and poor bone-binding capacity (18) , has little or no effect on ligand binding and only a small effect on enzyme inhibition-even though there are major effects in cell-based assays.
It is also of interest to see how these results with GGPPS compare with those we reported previously, with FPPS (39) . As can be seen in Fig. 5C , the four ΔH, ΔS values fall on the line discussed previously for six bisphosphonates (at 2 pH values) binding to FPPS from T. brucei (39) . What is surprising about the results is that the zoledronate/BPH-703 ΔS∕ΔH results are very close, as are the risedronate/BPH-811 results (Fig. 5C) . Moreover, the two sets of results are themselves quite close, with neither the extreme entropy or enthalpy driven behavior seen with FPPS (39), suggesting either that the charge center does not contribute to binding in GGPPS, or that the presence of the large neutral side chain simply reduces the effects of the cation center. The former view is supported by the observation in S. cerevisae GGPPS that the cation center is not essential for GGPPS inhibition (36) , unlike the situation with FPPS (3).
In Vivo Compound Activity. To assess the in vivo activity of the lipophilic bisphosphonates, we used a P.chabaudi suppressive test. We first injected mice with 10 6 parasites followed by 10 mg∕kg of each bisphosphonate, i.p., for 4 d. With BPH-703, there was a 100% reduction in parasitaemia (Fig. 6A ) and a 100% survival at day 14 (Fig. 6B) . There was weight loss during treatment, but this was regained after treatment. In the case of BPH-811, there was an approximately 80% decrease in parasitaemia and an 80% survival at day 14. We then carried out a second series of experiments using a reduced (3 mg∕kg, i.p.) dosing protocol. As with the 10 mg∕kg dose, the best results were obtained with BPH-703 ( Fig. 6 C and D) where there was a 100% survival (Fig. 6C) and only approximately 8% parasitaemia (Fig. 6D) 14 d after dosing. As can be seen in Table S1 , BPH-703 has good in vitro IC 50 and logP values and little effect on human cell lines, as well as good in vivo activity, and thus represents a potentially attractive lead for further development.
Conclusions
Overall, the results presented here are of interest because they show that GGPPS is a promising target for antimalarials and that the lipophilic analogs of the bone-resorption drugs zoledronate and risedronate have activity both in vitro as well as in vivo. BPH-703 is a lipophilic analog of zoledronate in which the 1-OH group is removed (to prevent bone binding) and the ring is alkylated to enhance lipophilicity-to increase cell permeability, decrease bone binding, and enhance tissue distribution. BPH-811 is an analog of risedronate in which, again, the 1-OH group is removed and a lipophilic tail added. Both compounds have potent activity in vitro and in vivo, whereas the parent drugs, zoledronate and risedronate, have only modest activity against P. falciparum in intraerythrocytic assays; and risedronate, although reducing parasitaemia, has no effect on survival (15) . Also of interest is the observation that the lipophilic bisphosphonate inhibitors in the Plasmodium GGPPS structures adopt very similar binding poses to those of their parent compounds bound to both GGPPS as well as FPPS, and have similar enzyme activity and ΔG values, for GGPPS binding. It thus seems likely that these and related lipophilic bisphosphonates will have improved activity over that already reported with more hydrophilic bisphosphonates (4-15) against other parasitic protozoa, such as T. brucei, T. cruzi, Leishmania spp., T. gondii, C. parvum, and E. histolytica.
Methods
High-throughput screening intracellular cell-growth inhibition assays for P. falciparum were carried out using parasite lactate dehydrogenase and SybrGreen assays; full details are given in SI Methods. PvGGPPS crystals were obtained as described previously (16) with some modifications and were cocrystallized with BPH-703 or BPH-811 to obtain the complex structures. Full details are given in SI Methods. Structure determinations and refinements were carried out basically as described previously (16) with full details given in SI Methods. PvGGPPS/bisphosphonate ITC experiments were carried out as described previously, for FPPS (39) .
